ACHV
NSCAchieve Life Sciences Inc.
Healthcare•Biotechnology
Watchlists:
Last updated: Friday 18th July 2025
2.75
+0.06 (2.23%)
Prev Close:2.69
Open:2.71
Bid:2.74
Ask:2.79
52 Week Range
1.845.31
Volume:771,264
Mkt Cap:92 M
30
MarketXLS Rank ®
Weak Hold
Price Target
$3.16
+14.9%
Debt To Equity Ratio (Historical)
LiveIt is used to evaluate a company's financial leverage and is calculated by dividing a company’s total liabilities by its shareholder equity. It is a measure of the degree to which a company is financing its operations through debt versus wholly owned funds
How calculated | Debt / Equity= Total Liabilities / Total Shareholders’ Equity
|
Example usage | =hf_Debt_to_Equity_Ratio("MSFT",2022) - Returns the value for the year 2022. =hf_Debt_to_Equity_Ratio("MSFT",2022,2) - Returns the value for the year 2022 and the calendar quarter 2 =hf_Debt_to_Equity_Ratio("MSFT",2022,3,"TTM") - Returns the value for the year 2022 and trailing twelve months from the calendar quarter =hf_Debt_to_Equity_Ratio("MSFT","lq") - Returns the value for the last quarter =hf_Debt_to_Equity_Ratio("MSFT","lq-1") - Returns the value for the last quarter-1 =hf_Debt_to_Equity_Ratio("MSFT","ly") - Returns the value for the last year =hf_Debt_to_Equity_Ratio("MSFT","ly-1") - Returns the value for the last year - 1 =hf_Debt_to_Equity_Ratio("MSFT","lt") - Returns the value for the last 12 months. =hf_Debt_to_Equity_Ratio("MSFT","lt-1") - Returns the value for the previous last 12 months. |
Notes | A “good” debt-to-equity (D/E) ratio will depend on the nature of the business and its industry. Generally speaking, a D/E ratio below 1.0 would be seen as relatively safe, whereas ratios of 2.0 or higher would be considered risky.
Some industries, such as banking, are known for having much higher D/E ratios than others. Note that a D/E ratio that is too low may actually be a negative signal, indicating that the firm is not taking advantage of debt financing to expand and grow |
Assets | Stocks |